Gert J Ossenkoppele Selected Research

Lymphoma (Lymphomas)

4/2010	Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles.
9/2006	Apoptosis resistance and response to chemotherapy in primary nodal diffuse large B-cell lymphoma.
8/2006	Human soluble TRAIL/Apo2L induces apoptosis in a subpopulation of chemotherapy refractory nodal diffuse large B-cell lymphomas, determined by a highly sensitive in vitro apoptosis assay.
4/2005	Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas.
3/2004	Emerging antibody-targeted therapy in leukemia and lymphoma: current concepts and clinical implications.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gert J Ossenkoppele Research Topics

Disease

72	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2022 - 02/2003
29	Leukemia 01/2022 - 02/2003
23	Neoplasms (Cancer) 11/2019 - 06/2002
14	Residual Neoplasm 01/2021 - 02/2003
12	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2019 - 04/2004
8	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 08/2017 - 11/2007
5	Pathologic Complete Response 12/2020 - 10/2005
5	Non-Hodgkin Lymphoma (Lymphosarcoma) 04/2011 - 07/2002
5	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 04/2010 - 04/2005
5	Lymphoma (Lymphomas) 04/2010 - 03/2004
5	B-Cell Lymphoma (Lymphoma, B Cell) 01/2008 - 04/2005
3	Acute Promyelocytic Leukemia 12/2020 - 08/2010
3	Refractory Anemia 01/2020 - 09/2009
3	Cytopenia 01/2019 - 08/2009
3	Blister (Bulla) 11/2015 - 01/2014
3	Philadelphia Chromosome 03/2015 - 11/2007
2	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 10/2010
2	Myeloid Leukemia (Leukemia, Myelocytic) 02/2016 - 01/2006
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 03/2015 - 04/2013
2	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 05/2014 - 01/2014
2	Wilms Tumor (Wilm's Tumor) 04/2013 - 01/2007
2	Breast Neoplasms (Breast Cancer) 05/2007 - 02/2003
2	Necrosis 08/2006 - 01/2003
2	Hyperthermia 01/2005 - 09/2003
1	Refractory Anemia with Excess of Blasts (RAEM) 01/2019
1	Chromosome Aberrations (Chromosome Abnormalities) 01/2019

Drug/Important Bio-Agent (IBA)

16	AntigensIBA 10/2018 - 08/2004
9	Cytarabine (Cytosar-U)FDA LinkGeneric 06/2017 - 04/2004
8	Peptides (Polypeptides)IBA 11/2015 - 01/2010
7	VaccinesIBA 10/2018 - 01/2006
7	Imatinib Mesylate (Gleevec)FDA Link 08/2013 - 11/2007
6	Pharmaceutical PreparationsIBA 01/2022 - 03/2011
6	Azacitidine (5 Azacytidine)FDA Link 12/2020 - 07/2012
6	Proteins (Proteins, Gene)FDA Link 02/2014 - 06/2002
5	Tretinoin (Retinoic Acid)FDA LinkGeneric 12/2020 - 08/2010
5	Tyrosine Kinase InhibitorsIBA 08/2017 - 04/2011
5	invariant chain (Ii-Key)IBA 06/2014 - 03/2010
4	Decitabine FDA Link 04/2022 - 08/2019
4	Biomarkers (Surrogate Marker)IBA 12/2021 - 03/2010
4	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 04/2007 - 07/2002
3	Lenalidomide (CC 5013)FDA Link 05/2021 - 04/2013
3	nilotinib FDA Link 08/2017 - 11/2007
3	AnthracyclinesIBA 06/2017 - 08/2010
3	Daunorubicin (Cerubidine)FDA LinkGeneric 06/2017 - 10/2005
3	Interleukin-4 (Interleukin 4)IBA 11/2015 - 01/2003
3	Histocompatibility Antigens Class IIIBA 04/2011 - 03/2010
3	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 05/2007 - 02/2003
3	valspodar (PSC 833)IBA 10/2005 - 02/2003
3	CaspasesIBA 04/2005 - 06/2002
2	Clofarabine (Clolar)FDA Link 01/2022 - 03/2017
2	Immunoconjugates (Immunoconjugate)IBA 01/2019 - 11/2004
2	RNA (Ribonucleic Acid)IBA 01/2018 - 01/2010
2	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 01/2010
2	EnzymesIBA 02/2016 - 02/2014
2	AminopeptidasesIBA 02/2016 - 10/2010
2	CytokinesIBA 04/2014 - 01/2003
2	Histone Deacetylase InhibitorsIBA 02/2014 - 07/2013
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2014 - 01/2003
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 04/2011 - 04/2009
2	HLA-DR Antigens (HLA-DR)IBA 04/2011 - 03/2010
2	Caspase 9IBA 01/2008 - 12/2007
2	7-aminoactinomycin DIBA 07/2005 - 09/2003
2	Fluorescent Dyes (Fluorescent Probes)IBA 07/2005 - 02/2003
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2003 - 01/2003
1	LectinsIBA 09/2021
1	NEO2734IBA 08/2021
1	enasidenibIBA 01/2021
1	ivosidenibIBA 01/2021
1	RNA Splicing FactorsIBA 01/2021
1	Antineoplastic Agents (Antineoplastics)IBA 01/2021
1	cc-486IBA 12/2020
1	AcidsIBA 12/2020
1	RetinoidsIBA 12/2020
1	Arsenic Trioxide (Trisenox)FDA Link 12/2020
1	PanobinostatIBA 01/2020
1	bisbenzimide ethoxide trihydrochloride (Hoechst 33342)IBA 01/2019
1	Bispecific AntibodiesIBA 01/2019
1	fms-Like Tyrosine Kinase 3IBA 01/2018
1	Indicators and Reagents (Reagents)IBA 01/2018
1	Amsacrine (AMSA)IBA 03/2017
1	Carboxylic Ester HydrolasesIBA 02/2016
1	Carboxylesterase (Hydrolase S)IBA 02/2016
1	EsterasesIBA 02/2016
1	ProdrugsIBA 02/2016
1	PlasticsIBA 02/2016
1	HLA Antigens (Human Leukocyte Antigens)IBA 03/2015
1	Phosphotransferases (Kinase)IBA 09/2014
1	ponatinibIBA 09/2014
1	EpitopesIBA 04/2014

Therapy/Procedure

32	Therapeutics 01/2021 - 07/2002
28	Drug Therapy (Chemotherapy) 01/2021 - 07/2002
12	Immunotherapy 01/2019 - 03/2004
11	Stem Cell Transplantation 01/2021 - 07/2005
7	Surgical Instruments (Clip) 06/2014 - 08/2004
5	Hematopoietic Stem Cell Transplantation 12/2020 - 03/2007
3	Induction Chemotherapy 12/2020 - 10/2005
2	Transplantation 04/2011 - 03/2007
2	Investigational Therapies (Experimental Therapy) 01/2011 - 01/2010
1	Precision Medicine 01/2021
1	Homologous Transplantation 01/2016